PAROXYSMAL NOCTURNAL HEMOGLOBINURIA THERAPEUTICS MARKET ANALYSIS
Global Paroxysmal Nocturnal Hemoglobinuria Therapeutics Market: Regional Analysis
North America is expected to dominate in paroxysmal nocturnal hemoglobinuria therapeutics market during the forecast period, owing to new approvals from the FDA. For instance, in 2018, Ravulizumab (Ultomiris) from Alexion Pharmaceuticals and APL2 from Apellis Pharmaceuticals was approved by the FDA, for the treatment of paroxysmal nocturnal hemoglobinuria.
Asia Pacific paroxysmal nocturnal hemoglobinuria therapeutics market size is expected to witness significant growth due to availability of cost-effective treatment and medical tourism for PNH. According to an article published by National Center for Biotechnology Information (NCBI) in 2014, the cost of bone marrow transplant in India was between US$ 10,000 and US$ 40,000 in 2014 and in the U.S., it was between US$ 73,000 and US$ 140,000 in 2012.
By Region
Paroxysmal Nocturnal Hemoglobinuria Therapeutics Market Report Snapshots
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize NowWant to Buy a Report but have a Limited Budget?
We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail
Request Discount
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients